Iron overload and toxicity: the hidden risk of multiple blood transfusions.
BACKGROUND
The quantity of iron in body is carefully regulated, primarily by control of iron absorption, and excess total body iron can be extremely toxic. Since humans have no mechanism for elimination of excess iron, multiple transfusions of red blood cells, which are required for the management of a number of disorders, inevitably result in iron overload. Cumulative iron overload, in turn, leads to iron toxicity with organ dysfunction and damage.


METHODS
This review examines the relationship between iron metabolism and hematologic disorders treated with multiple transfusions, with emphasis on the diagnosis and current methods of management of iron overload and toxicity in transfusion-dependent patients. Primarily using key words, we identified and reviewed more than 100 pertinent articles in English and other languages in the Medline database plus an additional number of abstracts of presentations at recent meetings of relevant scientific associations.


RESULTS
Transfusion-dependent disorders include those characterized by decreased red blood cell production, increased red blood cell destruction, or chronic blood loss. Patients receiving chronic transfusion therapy should be screened and monitored for iron overload, yet in our opinion, this is not always done routinely. Once iron overload has been identified, it should be treated to reduce the risk of morbidity and mortality from iron toxicity, which particularly affects the liver and heart.


CONCLUSIONS
Increased awareness of the risks of iron overload from chronic transfusion therapy should result in greater use of interventions such as iron chelation to reduce total body iron and the risk of long-term sequelae.
Shander
A
A
Department of Anesthesiology, Critical Care Medicine, and Hyperbaric Medicine, Englewood Hospital and Medical Center, Englewood, NJ 07631, USA. aryeh.shander@ehmc.com
Cappellini
M D
MD
Goodnough
L T
LT
D000740:Anemia / Q000628:therapy; D009202:Cardiomyopathies / Q000209:etiology; D002570:Ceruloplasmin / Q000172:deficiency; D015913:Chelation Therapy; D002908:Chronic Disease; D006432:Hemochromatosis / Q000150:complications; D006801:Humans; D007501:Iron / Q000009:adverse effects / Q000378:metabolism / Q000493:pharmacokinetics; D007502:Iron Chelating Agents / Q000627:therapeutic use; D019190:Iron Overload / Q000175:diagnosis / Q000209:etiology* / Q000503:physiopathology / Q000517:prevention & control / Q000628:therapy; D008107:Liver Diseases / Q000209:etiology; D018962:Phlebotomy; D012306:Risk; D014168:Transferrin / Q000378:metabolism; D065227:Transfusion Reaction
D007502:Iron Chelating Agents; D014168:Transferrin; D007501:Iron; D002570:Ceruloplasmin